A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.

NCT02034006 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Choroidal Neovascularization Secondary to Pathologic Myopia

Interventions

DRUG: Ranibizumab

Sponsor

Novartis Pharmaceuticals